Ertugliflozin + Sitagliptin
Uses of Ertugliflozin + Sitagliptin
Ertugliflozin + Sitagliptin is prescribed for the management of type 2 diabetes mellitus, aiding in the regulation of blood sugar levels.
How Ertugliflozin + Sitagliptin Works
Ertugliflozin inhibits the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and increasing urinary glucose excretion. Sitagliptin acts as a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhancing incretin hormone action, which stimulates insulin release and inhibits glucagon release.
Side Effects of Ertugliflozin + Sitagliptin
Common side effects include urinary tract infections, nasopharyngitis, headache, and hypoglycemia.
Warnings
Kidney Limited Data
Limited data are available regarding the impact of this medication on kidney function. Consultation with a healthcare professional is recommended for individuals with kidney issues.
Alcohol Limited Data
Limited data are available regarding the interaction of this medication with alcohol. Caution is advised, and it is recommended to consult with a healthcare professional before combining the two.
Pregnancy Limited Data
There is limited data on the safety of this medication during pregnancy. Consultation with a healthcare provider is recommended to assess potential risks and benefits.
Driving Generally Safe
This medication is generally considered safe for driving, but individual responses may vary. It is advisable to assess personal tolerance before engaging in activities that require alertness.
Liver Limited Data
Data on the effects of this medication on liver function are limited. Caution is advised, particularly for individuals with liver conditions. Consultation with a healthcare professional is recommended.
Lactation Limited Data
Limited data are available regarding the safety of this medication during lactation. Consultation with a healthcare professional is advised to determine potential risks and benefits.
Written by Dr Sri Viknarajan, MD (Universiti Hasanuddin, Indonesia)
Reviewed by Dr Nur Syuhada binti Zulkifli, MD, Universiti Kebangsaan Malaysia (UKM).
